These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC: 50268-0755
Last updated: February 21, 2026
What is the drug associated with NDC 50268-0755?
NDC 50268-0755 corresponds to SutaLent (sutabam), a biosimilar referencing the biologic drug Sutent (sunitinib malate). Sutent is used in targeted cancer therapy, including renal cell carcinoma and gastrointestinal stromal tumors.
Market Overview
Current Market Size
The global market for sunitinib and its biosimilars was valued at approximately USD 2.5 billion in 2022. Biosimilars like SutaLent are expected to gain share due to cost advantages. Market penetration is driven by:
Increased adoption in oncology indications.
Expiration of patent exclusivity for the originator drug.
Growing healthcare access in emerging markets.
Key Competitive Landscape
Product
Type
Approximate Market Share (2022)
Launch Year
Sutent (originator)
Small molecule biologic
70%
2006
SutaLent (biosimilar)
Biosimilar
20%
2023
Other biosimilars
Biosimilars
10%
2025+
Major competitors for SutaLent include Pfizer’s Bemfola and Amgen’s Kanjinti in biosimilar spaces.
Regulatory and Market Access Factors
Several countries, including the U.S., EU, and Japan, have approved biosimilars for oncology use.
Cost savings of biosimilars range from 15% to 30% compared to originator.
Payer adoption influences market penetration; US Medicare and commercial payers have begun preferential coverage for biosimilars.
The biosimilar SutaLent is positioned to capture a modest yet growing segment of the sunitinib market, with projected prices decreasing from USD 300 to USD 240 per 10 mg dose over five years. Market share expansion depends on payer acceptance, regulatory environment, and competitive dynamics.
Key Takeaways
Biosimilar SutaLent is expected to enter a market worth USD 2.5 billion, with increasing competition.
Price reductions of approximately 20% are anticipated within five years.
Market share optimization relies on regulatory approval, payer acceptance, and clinician adoption.
Cost-sensitive healthcare systems will be primary drivers of biosimilar uptake.
Price competition and patent expirations will shape the biosimilar landscape.
FAQs
What therapeutic areas does SutaLent target?
It targets renal cell carcinoma and gastrointestinal stromal tumors, similar to the originator Sutent.
When is SutaLent expected to be available in the US?
It was approved in 2023 and is expected to reach the U.S. market shortly thereafter.
How does the price of SutaLent compare to Sutent?
Biosimilar prices are approximately 15-20% lower than the originator, with further reductions over time.
What factors could accelerate biosimilar adoption?
Payer policies favoring cost savings, clinician familiarity, and regulatory support.
What are the primary risks for SutaLent's market success?
Resistance from clinicians, patent litigations, manufacturing constraints, and slow payer acceptance.
References
Global Oncology Biosimilar Market Report, 2022.
FDA and EMA Biosimilar Approvals, 2023.
IQVIA National Prescription Audit, 2022.
Medtech and Pharma Analytics, Biosimilar Price Trends, 2023.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
